World Health Innovation Summit CEO Gareth Presch visits St Anna CCRI

Sharing knowledge about childhood cancer with United Nations´ “Sustainable Development Goals (SDG) Cities”

We were very pleased to welcome Gareth Presch to St. Anna CCRI recently. Gareth is founder and CEO of the World Health Innovation Summit (https://whis.world/) and health care strategist with long lasting experience working in public, private and voluntary healthcare settings. A very stimulating tour of our institute by our leading expert on solid tumors, Heinrich Kovar, was followed by an open discussion on possible points of collaboration.

Besides other responsibilities – Gareth´s visit to St. Anna CCRI was mainly on behalf of United Nations Global Sustainability Index Institute as their SDG3 Health expert on SDG-Cities (https://www.ungsii.org https://www.sdg-cities.org/ ): SDG stands for sustainable development goals and this platform helps cities in low and middle income countries develop and improve quality of life.

“On the UN SDGs – SDG3 Good Health & Wellbeing – children’s cancer is one of our focus areas and we would be interested in exploring opportunities to work with St. Anna CCRI and collaborate with some of the Cities – (e.g. Kinshasa, Brasov, Sikkim),” explained Gareth.

Günter Koch, President at Humboldt Cosmos Multiversity & GRASPnetwork & ExC-Board Member of World Capital Institute, who took on the role of Austrian host, added: “Gareth has advised and been a member of a number of successful charity fundraising events in the past and continues to support charitable causes locally, nationally and internationally. We came together through a common affiliation with an organization called The New Club of Paris, of which I was one of three co-initiators in 2005, the mission of which was and is to set agendas in knowledge politics and policies. I think it will be of high interest to find out, if and how St. Anna CCRI can take advantage of Gareth´s activities, and, vice versa, Gareth will learn about St. Anna CCRI’s endeavors to manage promising R&D in the field of childhood cancer.”